- |||||||||| human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
A Recombinant BIO-HDL (CER-001) Can Prevent SARS-COV2-Induced Renal Dysfunction by Restoring SR-BI Signalling (Mini-Orals Hall) - May 5, 2022 - Abstract #ERAEDTA2022ERA_EDTA_1107; Consistent with in vitro results, analysis of renal biopsies from COVID-19 patients with proteinuria showed increased SR-BI and ACE-2 cytoplasmic signals and reduced expression at the apical domain of injured tubules. CONCLUSION Our data confirmed the key role of lipid profile in SARS-COV2 infection, evaluating the molecular signalling involved in HDL metabolism and inflammatory processes, and could offer new therapeutic strategies for COVID-19 patients.
- |||||||||| human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
Clinical, Journal: No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. (Pubmed Central) - Jun 24, 2021 CONCLUSION Our data confirmed the key role of lipid profile in SARS-COV2 infection, evaluating the molecular signalling involved in HDL metabolism and inflammatory processes, and could offer new therapeutic strategies for COVID-19 patients. In patients with genetically determined very low HDL-cholesterol, 24 weeks of treatment with HDL mimetic CER-001 did not reduce carotid vessel wall dimensions or arterial wall inflammation, compared with placebo.
- |||||||||| CER-209 / Abionyx Pharma
Clinical, Observational data, Journal: Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer Attending the Tikur Anbessa Specialized Hospital, Addis Ababa Ethiopia, 2019: A Cross-sectional Study. (Pubmed Central) - Jun 22, 2021 In general, the overall adherence to AHT was 77.5% for women with breast cancer. Factors such as types of adjuvant hormone therapy, lack of side effects, mastectomy, getting social support, and thorough therapeutic communication were strongly linked with adherence to them.
- |||||||||| human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
Trial completion date, Trial termination, Trial primary completion date: TANGO: CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases (clinicaltrials.gov) - Feb 11, 2019 P3, N=30, Terminated, Reverse cholesterol transport remains a challenging therapeutic pathway to be explored. Trial completion date: Dec 2017 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Oct 2018; Lack of efficacy
- |||||||||| human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
Trial completion: CARAT: CER-001 Atherosclerosis Regression ACS Trial (clinicaltrials.gov) - Jan 31, 2017 P2, N=301, Completed, Trial completion date: Dec 2017 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Oct 2018; Lack of efficacy Active, not recruiting --> Completed
- |||||||||| human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
Enrollment closed: CARAT: CER-001 Atherosclerosis Regression ACS Trial (clinicaltrials.gov) - Sep 2, 2016 P2, N=301, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
Enrollment open: CARAT: CER-001 Atherosclerosis Regression ACS Trial (clinicaltrials.gov) - Aug 5, 2015 P2, N=292, Recruiting, Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
Enrollment change: Exploratory Study of Plaque Regression (clinicaltrials.gov) - Jul 29, 2013 P2, N=10, Completed, Active, not recruiting --> Completed N=15 --> 10
- |||||||||| human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
Trial completion: Exploratory Study of Plaque Regression (clinicaltrials.gov) - Jul 29, 2013 P2, N=10, Completed, N=15 --> 10 Active, not recruiting --> Completed
- |||||||||| human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
New P2 trial: Exploratory Study of Plaque Regression (clinicaltrials.gov) - Jan 22, 2012 P2, N=10, Completed,
|